CHRONIC MYELOID LEUKEMIA

Refine Results:
All Categories Epidemiology and Etiology (5) Prevention and Screening (0) Diagnosis and Staging (8) Treatment (48) Supportive Oncology (1)

CME

Clinical Cliffhangers: Case-Based Challenges for the Risk Assessment and Prophylaxis of Tumor Lysis Syndrome
An interactive CME program provided by Med-IQ
OncologySTAT CME

News

Transplant Protocol Benefits Elderly With Hematologic Cancers
Elsevier Global Medical News, 2011 Nov 1, MA Moon
FDA: Increased Pulmonary Arterial Hypertension Risk Seen With Dasatinib
Elsevier Global Medical News, 2011 Oct 11, E Mechcatie
NICE Recommends Nilotinib for Chronic Myeloid Leukemia
Elsevier Global Medical News, 2011 Aug 17, J Smith
Stopping Dasatinib and Nilotinib Explored in Chronic Myeloid Leukemia
Elsevier Global Medical News, 2011 Jun 30, S Freeman
Biomarker Predicts Worse Outcome in Chronic Myeloid Leukemia
Elsevier Global Medical News, 2011 Jun 23, S Freeman
More News ›

Journal Scans: Research

Imatinib Resistance Due to a Novel Tri-Nucleotide Insertion in the SH2/C Lobe Interface of BCR/ABL Kinase Domain Between Position K357 and N358
Leuk Res, 2012 May 1, S Vaidya, et al
Therapy of Chronic Myeloid Leukaemia Can Benefit From the Activation of Stem Cells: Simulation Studies of Different Treatment Combinations
Br J Cancer, 2012 Apr 26, I Glauche, et al
Evaluation of Residual CD34(+) Ph(+) Progenitor Cells in Chronic Myeloid Leukemia Patients Who Have Complete Cytogenetic Response During First-Line Nilotinib Therapy
Cancer, 2012 Apr 19, M Defina, et al
BCR-ABL1 Doubling-Times More Reliably Assess the Dynamics of CML Relapse Compared With the BCR-ABL1 Fold-Rise: Implications for Monitoring and Management
Blood, 2012 Mar 19, S Branford, et al
Bosutinib Is Active in Chronic Phase Chronic Myeloid Leukemia After Imatinib and Dasatinib and/or Nilotinib Therapy Failure
Blood, 2012 Feb 27, HJ Khoury, et al
More Journal Scans: Research ›

Journal Scans: Review

The Expanding Options for Front-Line Treatment in Patients With Newly Diagnosed CML
Crit Rev Oncol Hematol, 2012 Apr 9, J Pinilla-Ibar, et al
Free Journal Content
Why Does My Patient Have Lymphadenopathy or Splenomegaly?
Hematol Oncol Clin North Am, 2012 Mar 14, G Motyckova, et al
Managing Side Effects of Tyrosine Kinase Inhibitor Therapy to Optimize Adherence in Patients with Chronic Myeloid Leukemia: The Role of the Midlevel Practitioner
J Support Oncol, 2012 Jan 1, M Cornelison , et al
Free Journal Content
Managing Resistance in Chronic Myeloid Leukemia
Blood Rev, 2011 Nov 1, S Roychowdhury, et al
First-line treatment of chronic myeloid leukemia: imatinib versus nilotinib and dasatinib
Community Oncology, 2011 Feb 1, NJ DiBella
Free Journal Content
More Journal Scans: Review ›

Expert Opinion

Seminal Articles—Growth Factor Support
2012 Mar 26, David Henry, et al
First-Line Therapy for CML: Nilotinib Comes of Age
Lancet Oncol, 2011 Sept 1, J Davies
Free Journal Content
CML—The Changing Landscape of Front-line Therapy: Part I: Interview With Dr. Jane Apperley
OncologySTAT Editorial Team, 2010 Nov 23, Interview by L Scott Zoeller
CML—What to do About Imatinib Resistance; When to Consider Transplant: Part II: Interview With Dr. Jane Apperley
OncologySTAT Editorial Team, 2010 Nov 23, Interview by L Scott Zoeller
ADAGIO Imatinib Nonadherence in CML Study: Clinical Implications
2009 Apr 22, Isabel Cunningham, et al
More Expert Opinion ›

OncologySTAT Mobile

Away from the office, hospital or computer? Put the power of Elsevier's vast oncology resources in your pocket!

Cancer Type

  • Bladder
  • Bone
  • Breast
  • Breast (ER-Positive)
  • CNS/Brain
  • Colon and Rectum
  • Endocrine System
  • Esophagus
  • GYN (Non-Ovary)
  • GYN (Ovary)
  • Head and Neck
  • Hodgkin's Lymphoma
  • Kidney (Renal Cell)
  • Leukemia
  • Liver and Bile Duct
  • Lung
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myeloproliferative Diseases
  • Non-Hodgkin's Lymphoma
  • Pancreas
  • Pediatric Cancers
  • Prostate
  • Rare Cancers
  • Skin
  • Soft-Tissue Sarcoma
  • Stomach
  • Testicle
    • Forgot your password?
    Not a member? Free registration